利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1650 条记录 (耗时 0.03 秒)

    PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE
    98.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE 审中-公开
    含有氢键和纳洛酮的药物组合物

    公开(公告)号：US20150283091A1

    公开(公告)日：2015-10-08

    申请号：US14441814

    申请日：2013-11-06

    申请人： PURDUE PHARMA

    发明人： Ricardo Alberto Vargas Rincon

    IPC分类号： A61K9/50 ,  A61K47/18 ,  A61K47/26 ,  A61K9/48 ,  A61K47/38 ,  A61K47/32 ,  A61K31/485 ,  A61K47/02

    CPC分类号： A61K9/5078 ,  A61K9/4808 ,  A61K9/4816 ,  A61K9/5031 ,  A61K9/5047 ,  A61K31/198 ,  A61K31/485 ,  A61K33/04 ,  A61K45/06 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

    摘要： There is described a prolonged release pharmaceutical dosage form comprising a plurality of coated beads, each of the coated beads comprising: (a) a granule; (b) a first layer coated on the granule, the first layer comprising: (i) hydromorphone or a pharmaceutically acceptable salt thereof, (ii) naloxone or a pharmaceutically acceptable salt thereof, (iii) an antioxidant compound, and (iii) a chelating compound; and (c) a second layer coated on the first layer, the second layer comprising a prolonged release agent. The dosage form has improved stability and dissolution properties. Another aspect of the invention relates to use of a combination of an antioxidant (such as sodium metabisulfite) and a chelating agent (such as ethylenedinitrotetraacetic acid disodium salt dihydrate) to improve the stability and/or dissolution properties of a prolonged release dosage form comprising (i) hydromorphone or a pharmaceutically acceptable salt thereof and (ii) naloxone or a pharmaceutically acceptable salt thereof.

    摘要翻译： 描述了包含多个涂覆珠粒的延长释放药物剂型，每个涂覆的珠粒包含：（a）颗粒; （b）涂覆在颗粒上的第一层，第一层包括：（i）氢吗啡酮或其药学上可接受的盐，（ii）纳洛酮或其药学上可接受的盐，（iii）抗氧化剂化合物，和（iii） 螯合化合物; 和（c）涂覆在第一层上的第二层，第二层包含延长的脱模剂。 剂型具有改善的稳定性和溶解性能。 本发明的另一方面涉及抗氧化剂（例如偏亚硫酸氢钠）和螯合剂（例如乙二胺四乙酸二钠盐二水合物）的组合的用途，以改善延长释放剂型的稳定性和/或溶解性质，其包含（ i）氢吗啡酮或其药学上可接受的盐和（ii）纳洛酮或其药学上可接受的盐。

    Method for non-cancer disease treatment combining statin and interferon agents
    100.
    发明申请
    Method for non-cancer disease treatment combining statin and interferon agents 审中-公开
    联合他汀和干扰素治疗非癌症疾病治疗方法

    公开(公告)号：US20150246096A1

    公开(公告)日：2015-09-03

    申请号：US14714996

    申请日：2015-05-18

    申请人： Stephen Benjamin Cantrell

    发明人： Stephen Benjamin Cantrell

    IPC分类号： A61K38/21 ,  A61K33/04 ,  A61K33/06 ,  A61K31/366

    CPC分类号： A61K38/212 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/505 ,  A61K33/04 ,  A61K33/06 ,  A61K38/21 ,  A61K38/215 ,  A61K38/217 ,  A61K45/06 ,  A61K2300/00

    摘要： A method for pharmacological treatment of cancer and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) or an angiogenesis inhibitor (a very similar and often overlapping group of drugs which inhibit blood vessel growth and maintenance, such as thalidomide, angiostatin, endostatin, or other agents), and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.

    摘要翻译： 提出了一种药物治疗癌症和其他疾病的方法，其中包括他汀类药物（Hmg-CoA还原酶抑制剂，如洛伐他汀，辛伐他汀，阿托伐他汀，西立伐他汀，氟伐他汀，普伐他汀或新药）与干扰素 例如干扰素α-2b或其他）或血管生成抑制剂（抑制血管生长和维持的非常相似且经常重叠的药物组，例如沙利度胺，血管抑素，内皮抑制素或其他药物），并且还包括同时施用 硒和钙。 本发明公开的方法是有用的，因为它可以证明比某些疾病以前已知的治疗更有效，并且因为其使用可能比其他方法更可耐受，更少的损伤，更便宜。 本文公开的方法可以容易地由本领域技术人员处理疾病复制。